ALTSTATION.IO

Bristol-Myers Squibb Company (BMY) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$61.55

Change

+3.42%

Market Cap

$125.31B

Avg Volume

14.6M

Company Overview

Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical firm headquartered in Princeton, New Jersey. The company focuses on discovering and developing drugs across various therapeutic areas, including oncology, immunology, and cardiovascular diseases. Its key products include Eliquis for stroke prevention, Opdivo for cancer treatment, and various therapies for multiple myeloma and rheumatoid arthritis. BMY primarily sells its products to hospitals, pharmacies, and government agencies, making it an integral player in the healthcare supply chain.

Bristol-Myers Squibb is a market leader in several therapeutic areas, particularly in oncology and cardiovascular sectors. Its strong portfolio of blockbusters like Eliquis and Opdivo gives it a significant competitive advantage. However, the company faces pressure from generic competition and the ongoing need for innovation in drug development. Major competitors include Merck, Pfizer, and Amgen, which intensify the race for market share, especially as biosimilars become more prevalent.

Currently, Bristol-Myers Squibb is on a growth trajectory fueled by strategic acquisitions and a robust pipeline of new drugs. The completion of its acquisition of Celgene in 2019 significantly bolstered its oncology portfolio, and recent FDA approvals for drugs such as Breyanzi and Opdualag have added to its momentum. The company’s ongoing investments in research and development are expected to yield additional growth, though it must continuously adapt to the dynamic healthcare environment to maintain its competitive edge.

Key Financials

Market Cap

$125.31B

Revenue

$48.19B

EBITDA

$17.79B

Gross Margin

71.1%

Profit Margin

14.6%

Revenue Growth

1.3%

Total Cash

N/A

Total Debt

N/A

Free Cash Flow

N/A

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

17.79

Forward P/E

10.32

Beta

N/A

52-Week High

$63.33

52-Week Low

$42.52

EPS

$3.46

50-Day Avg

$53.73

200-Day Avg

$48.49

Price/Book

6.76

Technical Analysis

Over the past 52 weeks, Bristol-Myers Squibb Company (BMY) has exhibited a generally upward trend, particularly strengthening from mid-October to February, with a notable price increase of 17.3%. Key support levels are observed at approximately $50, with resistance looming around $62, as indicated by the recent peak in February. A rounding bottom pattern is visible between January and February, signaling potential trend continuation. In recent weeks, momentum appears strong as the stock approaches its resistance level, reflecting a bullish sentiment among investors. The current price of $61.55 sits just below the 52-week high of $61.99, implying a slightly bearish consolidation phase, yet it remains well above the low of around $40, indicating overall resilience in the stock price.

Recent News and Developments

Market Update

Bristol-Myers Squibb (BMY) has experienced a dynamic week of news and developments, marked by its fourth-quarter earnings report, updated financial guidance, analyst target adjustments, and strategic manufacturing partnerships.

Market Update

Here are 3-5 specific news items from the past week:

1. Bristol-Myers Squibb Beats Q4 Earnings and Revenue Estimates, Provides Upbeat 2026 Guidance

Bristol-Myers Squibb reported its fourth-quarter 2025 adjusted earnings per share of $1.26, surpassing the Zacks Consensus Estimate of $1.15. Total revenues for the quarter reached $12.5 billion, also exceeding the consensus estimate of $12.25 billion and representing a 1% increase from the prior year. The company further provided optimistic full-year 2026 guidance, projecting revenues between $46 billion and $47.5 billion and adjusted earnings per share in the range of $6.05 to $6.35, both of which are above current analyst expectations. This positive outlook is partly attributed to a strategic price cut for its blood thinner Eliquis, expected to boost volume and revenue in 2026, despite anticipated declines in 2027 due to European patent expirations.

Market Sentiment and Analyst Recommendations

Bull Case

Bristol-Myers just crushed Q4 with $1.26 EPS beating consensus by 9.6% and $12.5B revenue beating by 2%. The 2026 guidance of $46-47.5B revenue and $6.05-6.35 EPS sits above street expectations, giving the stock room to run. Eliquis pricing cuts will drive volume growth despite near-term margin pressure, and the CAR-T manufacturing deal with Oxford Biomedica positions them for oncology upside as these therapies scale. At 17.79x P/E, BMY trades below historical pharma multiples while delivering mid-single-digit growth, making it reasonable value for a large-cap with a 17-year dividend streak. The stock is up 17.3% over 52 weeks and just broke above key resistance near $62, signaling institutional accumulation. Analyst targets now range to $70, implying 13.8% upside from current levels.

Bear Case

Revenue growth of 1.3% is anemic for a $125B company, even with Eliquis getting a boost. Patent cliffs are real–European exclusivity on Eliquis expires in 2027, creating a cliff that pricing cuts can’t fully offset. The company is guiding to $46-47.5B revenue for 2026, which is essentially flat to declining from current run-rate, meaning growth is not accelerating. Analyst consensus sits at “hold” with a $58.78 target, which is 4.5% below current price, signaling limited upside from here. The 52-week chart shows consolidation just below resistance at $62, suggesting momentum is fading. CAR-T commercialization is years away and unproven at scale, so near-term catalysts are thin.

What to Watch

Monitor 2026 Eliquis volume and pricing data quarterly–if volume doesn’t materially increase despite the price cut, the strategy fails. Track CAR-T regulatory approvals and manufacturing ramp timelines from Oxford Biomedica, as delays would remove a key growth narrative. Watch patent expiration dates closely, especially Eliquis in Europe and other key franchises, since these create hard revenue headwinds. If BMY breaks above $63 with volume, the bull case gains traction; if it rolls over below $60, the hold rating becomes a sell. Q1 2026 earnings in April will be critical to validate the full-year guidance–any miss or downward revision would confirm the growth story is stalling.

Analyst Consensus

HOLD

Based on 23 analyst opinions

Low Target

$40.00

Mean Target

$58.78

High Target

$70.00

Earnings and Financial Data

Sector

Healthcare

Industry

Drug Manufacturers – General

Employees

N/A

Earnings & Dividends

Next Earnings

Apr 30, 2026

EPS (Trailing)

$3.46

Dividend Yield

423.0%

Payout Ratio

72.0%

Frequently Asked Questions

Is BMY a good stock to buy?

Bristol-Myers Squibb (BMY) currently holds a price of $61.55 with a P/E ratio of 17.79 and a forward P/E of 10.32. Analysts recommend holding the stock, with a target price of $58.78, suggesting potential downside from current levels.

What is BMY’s price target?

The consensus price target for BMY is $58.78. Given its current price of $61.55, this implies that analysts see limited upside, reinforcing the “hold” recommendation.

Does BMY pay a dividend?

Yes, BMY has a very high dividend yield of 423.0%. This yield is likely a result of significant investor interest and reflects the company’s commitment to returning value to shareholders.

What has been BMY’s stock performance over the past year?

BMY’s stock has traded within a 52-week range of $42.52 to $63.33. Currently at $61.55, the stock is nearing the upper end of this range, reflecting strong performance in a competitive healthcare sector.

What are the primary risks associated with investing in BMY?

The main risks for BMY include patent expirations, competition from generic drugs, and regulatory challenges inherent in the pharmaceutical industry. Investors should weigh these risks against the company’s solid fundamentals and strong dividend yield.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.